64724-29-4 Usage
Description
Z-(1)-ETHOXY-(2)-(TRIBUTYLSTANNYL)ETHYLEN, also known as cis-1-Ethoxy-2-(tri-n-butylstannyl)ethylene, is an organic compound with a unique structure that features an ethoxy group at the 1st position and a tributylstannyl group at the 2nd position. Z-(1)-ETHOXY-(2)-(TRIBUTYLSTANNYL)ETHYLEN is known for its versatile applications in various fields, particularly in pharmaceutical research and as a reagent.
Uses
Used in Pharmaceutical Research:
Z-(1)-ETHOXY-(2)-(TRIBUTYLSTANNYL)ETHYLEN is used as a research compound for its potential applications in the development of new pharmaceuticals. Its unique structure allows for the exploration of its interactions with biological targets and its potential therapeutic effects.
Used as a Reagent:
In the field of chemistry, Z-(1)-ETHOXY-(2)-(TRIBUTYLSTANNYL)ETHYLEN serves as a valuable reagent due to its specific chemical properties. It can be utilized in various chemical reactions and synthesis processes, contributing to the development of new compounds and materials.
Check Digit Verification of cas no
The CAS Registry Mumber 64724-29-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,4,7,2 and 4 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 64724-29:
(7*6)+(6*4)+(5*7)+(4*2)+(3*4)+(2*2)+(1*9)=134
134 % 10 = 4
So 64724-29-4 is a valid CAS Registry Number.
InChI:InChI=1/C4H7O.3C4H9.Sn/c1-3-5-4-2;3*1-3-4-2;/h1,3H,4H2,2H3;3*1,3-4H2,2H3;/rC16H34OSn/c1-5-9-13-18(14-10-6-2,15-11-7-3)16-12-17-8-4/h12,16H,5-11,13-15H2,1-4H3/b16-12-
64724-29-4Relevant articles and documents
COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS
-
Page/Page column 72, (2015/03/28)
The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.
HETEROCYCLIC COMPOUNDS
-
Page/Page column 30; 31, (2009/08/18)
The invention relates to compounds of formula I and salts thereof wherein the substituents are as defined in the specification, processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.
FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS
-
Page/Page column 50, (2010/11/26)
In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, part